Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies.

Mallick R, Jolles S, Kanegane H, Agbor-Tarh D, Rojavin M.

J Clin Immunol. 2018 Nov;38(8):886-897. doi: 10.1007/s10875-018-0562-3. Epub 2018 Nov 21.

2.

Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.

Tortorici MA, Lawo JP, Weide R, Jochems J, Puli S, Hofmann J, Pfruender D, Rojavin MA.

Int Immunopharmacol. 2019 Jan;66:119-126. doi: 10.1016/j.intimp.2018.11.008. Epub 2018 Nov 15.

3.

Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.

Jolles S, Rojavin MA, Lawo JP, Nelson R Jr, Wasserman RL, Borte M, Tortorici MA, Imai K, Kanegane H.

J Clin Immunol. 2018 Nov;38(8):864-875. doi: 10.1007/s10875-018-0560-5. Epub 2018 Nov 10. Review.

4.

Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema.

Fox J, Vegh AB, Martinez-Saguer I, Wuillemin WA, Edelman J, Williams-Herman D, Rojavin M, Rosenberg T.

Allergy Asthma Proc. 2017 May 1;38(3):216-221. doi: 10.2500/aap.2017.38.4038.

PMID:
28441992
5.

Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema.

Craig T, Shapiro R, Vegh A, Baker JW, Bernstein JA, Busse P, Magerl M, Martinez-Saguer I, Riedl MA, Lumry W, Williams-Herman D, Edelman J, Feuersenger H, Machnig T, Rojavin M.

Allergy Rhinol (Providence). 2017 Mar 1;8(1):13-19. doi: 10.2500/ar.2017.8.0192.

6.

Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patients.

Busse P, Baker J, Martinez-Saguer I, Bernstein JA, Craig T, Magerl M, Riedl M, Shapiro R, Frank M, Lumry W, Rosch J, Edelman J, Williams-Herman D, Feuersenger H, Rojavin M; Berinert Registry Investigators.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1142-1145. doi: 10.1016/j.jaip.2016.12.033. Epub 2017 Mar 9. No abstract available.

PMID:
28286153
7.

Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry.

Magerl M, Frank M, Lumry W, Bernstein J, Busse P, Craig T, Martinez-Saguer I, Riedl MA, Shapiro R, Edelman J, Williams-Herman D, Wood DN, Feuersenger H, Rojavin M; Berinert Registry Investigators.

Ann Allergy Asthma Immunol. 2017 Jan;118(1):110-112. doi: 10.1016/j.anai.2016.10.006. Epub 2016 Nov 16. No abstract available.

8.

Assessment of inhibitory antibodies in patients with hereditary angioedema treated with plasma-derived C1 inhibitor.

Farkas H, Varga L, Moldovan D, Obtulowicz K, Shirov T, Machnig T, Feuersenger H, Edelman J, Williams-Herman D, Rojavin M.

Ann Allergy Asthma Immunol. 2016 Nov;117(5):508-513. doi: 10.1016/j.anai.2016.08.025. Epub 2016 Oct 24.

9.

Use of a C1 Inhibitor Concentrate in Adults ≥65 Years of Age with Hereditary Angioedema: Findings from the International Berinert® (C1-INH) Registry.

Bygum A, Martinez-Saguer I, Bas M, Rosch J, Edelman J, Rojavin M, Williams-Herman D; Berinert Registry Investigators.

Drugs Aging. 2016 Nov;33(11):819-827.

10.

Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data.

Riedl MA, Bygum A, Lumry W, Magerl M, Bernstein JA, Busse P, Craig T, Frank MM, Edelman J, Williams-Herman D, Feuersenger H, Rojavin M; Berinert Registry investigators.

J Allergy Clin Immunol Pract. 2016 Sep-Oct;4(5):963-71. doi: 10.1016/j.jaip.2016.04.018. Epub 2016 Jun 8.

11.

Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency.

Rojavin MA, Hubsch A, Lawo JP.

J Clin Immunol. 2016 Apr;36(3):210-9. doi: 10.1007/s10875-016-0243-z. Epub 2016 Feb 24.

12.

Safety of C1-esterase inhibitor in acute and prophylactic therapy of hereditary angioedema: findings from the ongoing international Berinert patient registry.

Busse P, Bygum A, Edelman J, Lumry W, Machnig T, Martinez-Saguer I, Rojavin M.

J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):213-9. doi: 10.1016/j.jaip.2014.08.014. Epub 2014 Oct 29.

PMID:
25609333
13.

Subcutaneous immunoglobulin loading regimens for previously untreated patients with primary antibody deficiency.

Rojavin M, Sidhu J, Pfister M, Hubsch A.

Clin Exp Immunol. 2014 Dec;178 Suppl 1:146-8. doi: 10.1111/cei.12548. No abstract available.

14.
15.

Clinical experience with an L-proline–stabilized 10 %intravenous immunoglobulin (Privigen®): real-life effectiveness and tolerability.

Dorsey MJ, Ho V, Mabudian M, Soler-Palacín P, Domínguez-Pinilla N, Rishi R, Rishi R, Wong D, Rojavin M, Hubsch A, Berger M.

J Clin Immunol. 2014 Oct;34(7):804-12. doi: 10.1007/s10875-014-0070-z. Epub 2014 Jul 1.

16.

Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.

Kanegane H, Imai K, Yamada M, Takada H, Ariga T, Bexon M, Rojavin M, Hu W, Kobayashi M, Lawo JP, Nonoyama S, Hara T, Miyawaki T.

J Clin Immunol. 2014 Feb;34(2):204-11. doi: 10.1007/s10875-013-9985-z. Epub 2014 Feb 7.

17.

Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease.

Jolles S, Borte M, Nelson RP Jr, Rojavin M, Bexon M, Lawo JP, Wasserman RL.

Clin Immunol. 2014 Feb;150(2):161-9. doi: 10.1016/j.clim.2013.10.008. Epub 2013 Oct 26.

18.

Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency.

Landersdorfer CB, Bexon M, Edelman J, Rojavin M, Kirkpatrick CM, Lu J, Pfister M, Sidhu J.

Postgrad Med. 2013 Nov;125(6):53-61. doi: 10.3810/pgm.2013.11.2712.

PMID:
24200761
19.

Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks.

Craig TJ, Rojavin MA, Machnig T, Keinecke HO, Bernstein JA.

Ann Allergy Asthma Immunol. 2013 Sep;111(3):211-5. doi: 10.1016/j.anai.2013.06.021. Epub 2013 Jul 16.

PMID:
23987198
20.

Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks.

Craig TJ, Bewtra AK, Hurewitz D, Levy R, Janss G, Jacobson KW, Packer F, Bernstein JA, Rojavin MA, Machnig T, Keinecke HO, Wasserman RL.

Allergy Asthma Proc. 2012 Jul-Aug;33(4):354-61. doi: 10.2500/aap.2012.33.3589.

PMID:
22856636
21.

C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks--final results of the I.M.P.A.C.T.2 study.

Craig TJ, Bewtra AK, Bahna SL, Hurewitz D, Schneider LC, Levy RJ, Moy JN, Offenberger J, Jacobson KW, Yang WH, Eidelman F, Janss G, Packer FR, Rojavin MA, Machnig T, Keinecke HO, Wasserman RL.

Allergy. 2011 Dec;66(12):1604-11. doi: 10.1111/j.1398-9995.2011.02702.x. Epub 2011 Sep 2.

PMID:
21884533
22.

Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.

Wasserman RL, Melamed I, Nelson RP Jr, Knutsen AP, Fasano MB, Stein MR, Rojavin MA, Church JA.

Clin Pharmacokinet. 2011 Jun;50(6):405-14. doi: 10.2165/11587030-000000000-00000.

PMID:
21553933
23.

Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.

Berger M, Rojavin M, Kiessling P, Zenker O.

Clin Immunol. 2011 May;139(2):133-41. doi: 10.1016/j.clim.2011.01.006. Epub 2011 Jan 23.

PMID:
21353644
24.

Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.

Hagan JB, Fasano MB, Spector S, Wasserman RL, Melamed I, Rojavin MA, Zenker O, Orange JS.

J Clin Immunol. 2010 Sep;30(5):734-45. doi: 10.1007/s10875-010-9423-4. Epub 2010 May 8.

25.

Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen, at different infusion rates.

Sleasman JW, Duff CM, Dunaway T, Rojavin MA, Stein MR.

J Clin Immunol. 2010 May;30(3):442-8. doi: 10.1007/s10875-010-9373-x. Epub 2010 Mar 10.

PMID:
20217199
26.

Patient recruitment and retention: From art to science.

Rojavin M.

Contemp Clin Trials. 2009 Sep;30(5):387. doi: 10.1016/j.cct.2009.06.002. Epub 2009 Jun 9. No abstract available.

PMID:
19520190
27.

Factors motivating dyspepsia patients to enter clinical research.

Rojavin MA, Downs P, Shetzline MA, Chilingerian R, Cohard-Radice M.

Contemp Clin Trials. 2006 Apr;27(2):103-11. Epub 2006 Jan 18.

PMID:
16413229
28.

Functional dyspepsia, delayed gastric emptying, and impaired quality of life.

Talley NJ, Locke GR 3rd, Lahr BD, Zinsmeister AR, Tougas G, Ligozio G, Rojavin MA, Tack J.

Gut. 2006 Jul;55(7):933-9. Epub 2005 Dec 1.

29.

Recruitment index as a measure of patient recruitment activity in clinical trials.

Rojavin MA.

Contemp Clin Trials. 2005 Oct;26(5):552-6.

PMID:
15990360
30.

Omeprazole-induced slowing of gastrointestinal transit in mice can be countered with tegaserod.

Cowan A, Earnest DL, Ligozio G, Rojavin MA.

Eur J Pharmacol. 2005 Jul 4;517(1-2):127-31.

PMID:
15972210
31.

Omeprazole delays gastric emptying in healthy volunteers: an effect prevented by tegaserod.

Tougas G, Earnest DL, Chen Y, Vanderkoy C, Rojavin M.

Aliment Pharmacol Ther. 2005 Jul 1;22(1):59-65.

32.

Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome.

Tougas G, Snape WJ Jr, Otten MH, Earnest DL, Langaker KE, Pruitt RE, Pecher E, Nault B, Rojavin MA.

Aliment Pharmacol Ther. 2002 Oct;16(10):1701-8.

33.

Reactions of keratinocytes to in vitro millimeter wave exposure.

Szabo I, Rojavin MA, Rogers TJ, Ziskin MC.

Bioelectromagnetics. 2001 Jul;22(5):358-64.

PMID:
11424160
34.

Peripheral neural system involvement in hypoalgesic effect of electromagnetic millimeter waves.

Radzievsky AA, Rojavin MA, Cowan A, Alekseev SI, Radzievsky AA Jr, Ziskin MC.

Life Sci. 2001 Jan 26;68(10):1143-51.

PMID:
11228098
35.

Hypoalgesic effect of millimeter waves in mice: dependence on the site of exposure.

Radzievsky AA, Rojavin MA, Cowan A, Alekseev SI, Ziskin MC.

Life Sci. 2000 Apr 14;66(21):2101-11.

PMID:
10823349
36.

Pain relief caused by millimeter waves in mice: results of cold water tail flick tests.

Rojavin MA, Radzievsky AA, Cowan A, Ziskin MC.

Int J Radiat Biol. 2000 Apr;76(4):575-9.

PMID:
10815639
37.

Suppression of pain sensation caused by millimeter waves: a double-blinded, cross-over, prospective human volunteer study.

Radzievsky AA, Rojavin MA, Cowan A, Ziskin MC.

Anesth Analg. 1999 Apr;88(4):836-40.

PMID:
10195534
38.

Antipruritic effect of millimeter waves in mice: evidence for opioid involvement.

Rojavin MA, Cowan A, Radzievsky AA, Ziskin MC.

Life Sci. 1998;63(18):PL251-7.

PMID:
9806220
39.

Medical application of millimetre waves.

Rojavin MA, Ziskin MC.

QJM. 1998 Jan;91(1):57-66. Review. No abstract available.

PMID:
9519213
40.
41.

Interaction of cyclophosphamide and ketamine in vivo.

Rojavin MA, Tsygankov AY, Ziskin MC.

Neuroimmunomodulation. 1996 Nov-Dec;3(6):333-5.

PMID:
9266543
42.

Effect of millimeter waves on survival of UVC-exposed Escherichia coli.

Rojavin MA, Ziskin MC.

Bioelectromagnetics. 1995;16(3):188-96.

PMID:
7677795
43.

Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids.

Szabo I, Rojavin M, Bussiere JL, Eisenstein TK, Adler MW, Rogers TJ.

J Pharmacol Exp Ther. 1993 Nov;267(2):703-6.

PMID:
8246144
44.

Morphine treatment in vitro or in vivo decreases phagocytic functions of murine macrophages.

Rojavin M, Szabo I, Bussiere JL, Rogers TJ, Adler MW, Eisenstein TK.

Life Sci. 1993;53(12):997-1006.

PMID:
8361330

Supplemental Content

Loading ...
Support Center